Table 7.

Treatment, modality and survival indicators of patients with CPFE-LC in the Meta-analysis.

Variables	N (study)a	Pooled data, 95%CI	P	Heterogeneity testing model
Treatment
Chemotherapy	5	0.387 (0.329,0.445)	0.052	Fixed
Radiotherapy	4	0.151 (0.028,0.337)	<0.001	Random
Surgery	4	0.318 (0.259,0.377)	0.838	Fixed
Other treatment	3	0.272 (0.163,0.380)	0.122	Random
Survival and mortality indicators
Mortality rate	3	0.720 (0.657,0.783)	0.365	Fixed
Five-year survival rate	3	0.250 (0.133,0.368)	0.486	Fixed
Cause of death
Lung cancer	8	0.238 (0.134,0.359)	<0.001	Random
AEILD	8	0.219 (0.145,0.302)	0.020	Random
Infection	3	0.268 (0.065,0.471)	0.010	Random
Not related to CPFE and LC	4	0.079 (0.046,0.111)	0.386	Fixed
Other causes	6	0.306 (0.129,0.482)	<0.001	Random
After surgery
Mortality rate at 90 days	3	0.074 (0.036,0.121)	0.627	Fixed
Acute exacerbation	2	0.143 (0.068,0.218)	0.158	Fixed
Died of lung cancer	5	0.220 (0.132,0.322)	0.355	Fixed
Died of respiratory failure	3	0.392 (0.245,0.638)	0.258	Fixed
Died of other causes	2	0.344 (0.179,0.508)	0.923	Fixed

Abbreviations: AEILD: acute exacerbation of interstitial lung disease. anumbers of studies included in the meta-analysis.